Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma
What is the purpose of this trial?
The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.
- Trial withYale Cancer Center
- Start Date03/23/2019
- End Date12/30/2019
- Last Updated05/19/2019
- Study HIC#2000021483